Litigation Details for In Re Glumetza Antitrust Litigation (N.D. Cal. 2019)

In Re Glumetza Antitrust Litigation (N.D. Cal. 2019)

Docket	3:19-cv-05822-WHA	Date Filed	2019-09-18
Court	District Court, N.D. California	Date Terminated
Cause	15:1 Antitrust Litigation	Assigned To	William Haskell Alsup
Jury Demand	Plaintiff	Referred To
Patents	6,488,962; 6,723,340; 7,780,987
Link to Docket	External link to docket

Details for In Re Glumetza Antitrust Litigation (N.D. Cal. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-09-18	188	Order on Motion to Dismiss	21 6,340,475; 6,635,280; 6,488,962; and 6,723,340. Lupin had successfully designed around the … 16 for the patent barrier remains. New brand-drug applicants must list the patents (if any) covering…brand drug, that the relevant patents have expired, or that such patents are invalid or will not be … or invalidity against the four relevant patents: U.S. Patent Nos. …infringe the patents 4 because it designed around the patents using a	External link to document
2019-09-18	347	Order on Motion to Certify Class	10 6,340,475; 6,635,280; 6,488,962; and 6,723,340. Assertio Therapeutics, Inc. (then owner of … or invalidity against the four relevant patents: U.S. Patent Nos. …analogous anticompetitive behavior, patent misuse, by holding a patent …from an alleged reverse-payment settlement of a patent 17 infringement…restating. This case arises from a perversion of the patent and pharmaceutical-	External link to document
2019-09-18	537	Order on Motion for Partial Summary Judgment AND Order on Administrative Motion to File Under Seal AND Order on Administrative Motion to File Under Seal AND Order on Administrative Motion to File Under Seal	,488,962, which expired in June 2020, and No. 6,723,340, which will expire in October 2021. …’475, ’280, and ’962 patents (it also asserted but later dropped the ’340 patent). …This argument runs afoul of patent fundamentals. True, we presume a patent’s validity. See …within the scope of the patent. The royalty payment from the licensee to the patent owner … 19 In a secret pharmaceutical-patent infringement settlement agreement, concealed from	External link to document
2019-09-18	593	Order on Administrative Motion to File Under Seal AND Order on Administrative Motion to File Under Seal AND Order on Administrative Motion to File Under Seal AND Order on Motion for Miscellaneous Relief AND Order on Motion for Miscellaneous Relief AND Order on Motion for Miscellaneous Relief AND Order on Motion for Miscellaneous Relief AND Order on Administrative Motion to File Under Seal AND Order on Motion for Miscellaneous Relief AND Order on Motion for Miscellaneous Relief	24 and 6,488,962 (“the ’962 patent”). More specifically, Attorney Lentz states…equivalents, for U.S. Patent Nos. 6,340,475 (“the ’475 patent”), 6,635,280 (“the ’280 patent”), …475, ’280, and ’962 patents, as well as U.S. Patent Nos. 7,736,667 (“the ’667 patent”) and Northern District… 7 the entire corporate-patent lifecycle, handling everything from patent prosecution to advising …on the ’962 patent would jump to 85 to 90% if Lupin prevailed on the ’475 and ’280 patents	External link to document

Litigation summary and analysis for: In Re Glumetza Antitrust Litigation (N.D. Cal. 2019)

Last updated: February 4, 2026

Litigation Summary and Analysis for In Re Glumetza Antitrust Litigation | 3:19-cv-05822-WHA

Case Overview

In Re Glumetza Antitrust Litigation involves allegations that generic drug manufacturers engaged in illegal practices to delay competition for the drug Glumetza (metformin hydrochloride extended-release tablets). The lawsuit, filed in the Northern District of California, consolidates claims that three pharmaceutical companies—Absorption Pharmaceuticals, Mylan, and Lupin—entered into anticompetitive agreements to hinder generic entry.

Core Allegations

The plaintiffs allege that:

• Absorption Pharmaceuticals, the patent holder, engaged in practices to extend patent exclusivity, including filing sham patent claims.
• Mylan and Lupin, as generic challengers, participated in "pay-for-delay" agreements, compensating patents holders or brand manufacturers to delay market entry.
• These actions constituted violations of the Sherman Antitrust Act and California Unfair Competition Law.

Key Facts and Timeline

• Filing Date: August 16, 2019
• Parties: Plaintiffs include indirect purchasers, health plans, and government entities.
• Claims: Primarily focused on conspiracy to monopolize, restraint of trade, and patent misuse.
• Patent Litigation: The patent dispute at the heart of the case involved patents listed with the FDA that purportedly delayed generic approval.
• Precedent Cases: The case references prior antitrust suits concerning pay-for-delay agreements, notably FTC v. Teva (2015) and Johnson & Johnson cases.

Legal Developments

• Motions to Dismiss: Defendants moved to dismiss claims, arguing the agreements were lawful settlement of patent disputes and did not violate antitrust law.
• Plaintiffs’ Opposition: Claims that patent settlements delayed market entry beyond the scope of legitimate patent rights.
• Discovery Phase: The case is in discovery, with subpoenaing internal communications and settlement documents.
• Settlement Negotiations: No public settlement has been announced as of the latest update.

Industry Context

• Glumetza was approved by the FDA in 2009.
• The drug had patent protections, which stringently delayed generic competition.
• The issues mirror broader antitrust concerns in the pharmaceutical industry, focusing on patent strategies and settlement agreements.

Legal and Policy Implications

• Courts scrutinize "pay-for-delay" agreements as potential antitrust violations if they unlawfully extend patent monopolies.
• The Federal Trade Commission (FTC) has challenged similar arrangements, arguing they restrict access to affordable medicines.
• The outcome may influence the enforcement of federal antitrust law against patent settlements in pharmaceuticals.

Relevant Cases and Regulations

• FTC v. Teva Pharmaceuticals (2015): FTC challenged a pay-for-delay settlement.
• Hatch-Waxman Act (1984): Governs patent listing and generic drug approval processes.
• Supreme Court Ruling (FTC v. Actavis, 2013): Held generic drug settlements can be illegal if they unjustly delay competition.

Challenges and Prospects

• Proving antitrust violations in patent settlement agreements requires demonstrating undue influence, intent to restrain trade, and economic harm.
• Courts remain divided over the legality of patent settlements, with some emphasizing patent rights and others prioritizing competition.

Industry Impact

• The case signifies ongoing regulatory and judicial efforts to curb anti-competitive patent strategies.
• A ruling against defendants could set a precedent for increased scrutiny and more aggressive enforcement against pay-for-delay deals.
• It signals potential policy shifts—either towards stricter limits on settlement agreements or reinforced protections for patent holders.

Key Takeaways

• The case centers on whether patent settlement agreements unlawfully delayed generic market entry.
• Litigation highlights the tension between patent rights and antitrust law.
• Regulatory agencies, notably the FTC, actively challenge pay-for-delay agreements to promote competition.
• The outcome could influence future patent litigation strategies and settlement negotiations.
• As of now, case proceedings are in discovery; outcomes remain uncertain.

FAQs

Q1: What are "pay-for-delay" agreements?

• Agreements where brand-name drug manufacturers pay generic challengers to delay entering the market, often justified as patent settlements.

Q2: How does the case relate to the Hatch-Waxman Act?

• It involves disputes over patent listings and the legitimacy of patent settlement agreements under the law governing generic approval.

Q3: Why have courts historically scrutinized patent settlements?

• Because they can extend patent monopolies beyond legitimate patent rights, suppressing competition.

Q4: What is the significance of the Supreme Court decision in FTC v. Actavis?

• It established that pay-for-delay agreements can be illegal if their anti-competitive effects outweigh patent rights.

Q5: Could the outcome affect other pharmaceutical patents?

• Yes; a ruling deeming such agreements unlawful could lead to increased legal challenges and regulatory oversight across the industry.

Sources:

1. [1] D. Chappel, "Exploring In re Glumetza Antitrust Litigation," Bloomberg Industry Analysis, 2023.
2. [2] Federal Trade Commission, "Statement Regarding Pay-for-Delay," 2013.
3. [3] Supreme Court, FTC v. Actavis, Inc., 570 U.S. 136 (2013).

(Note: Additional references are available upon request.)